Skip to main content
. 2023 Jul 25;13:12020. doi: 10.1038/s41598-023-39014-8

Table 5.

Univariate and multivariate analysis of overall survival in the patients classified into FIGO 2018 stage IIIC2p.

Variables Univariate Multivariate
(No. of patients) HR 95% CI p value HR 95% CI p value
Age (continuous) 0.986 0.957–1.017 0.959 0.909–1.009
Histology
 SCC (46) 1 (reference) 1 (reference)
 nSCC (30) 1.017 0.790–3.269 0.191 1.303 0.412–4.125 0.652
pT classificaion
 T1b (21) 1 (reference) 1 (reference)
 T2a (10) 1.261 0.315–5.048 0.743 0.872 0.135–5.615 0.885
 T2b (45) 2.344 0.946–5.806 0.066 1.497 0.345–6.498 0.590
 T2a 1 (reference) 1 (reference)
 T2b 1.859 0.556–6.216 0.314 1.717 0.342–8.611 0.511
Tumor diameter
 ≤ 40 mm (44) 1 (reference) 1 (reference)
 > 40 mm (31) 2.178 1.057–4.488 0.035 1.881 0.541–6.535 0.320
Stromal invasion
 ≤ 1/2 (7) 1 (reference) 1 (reference)
 > 1/2 (57) 2.699 0.364–19.996 0.331 0.841 0.095–7.479 0.877
Ovarian metastasis
 Negative/preserved (65) 1 (reference) 1 (reference)
 Positive (11) 1.447 0.554–3.777 0.451 0.611 0.066–5.678 0.665
Corpus invasion
 Negative (49) 1 (reference) 1 (reference)
 Positive (27) 1.631 0.803–3.314 0.176 1.394 0.441–4.400 0.572
Adjuvant therapy
 CCRT (26) 1 (reference) 1 (reference)
 CT (34) 0.875 0.337–2.270 0.783 0.908 0.220–3.738 0.893
 RT (10) 5.707 2.112–15.423  < 0.001 5.694 1.346–24.084 0.018
 None (2) 10.324 1.179–90.391 0.035 31.191 1.509–644.748 0.026
 CT 1 (reference) 1 (reference)
 RT 6.526 2.506–16.999  < 0.001 6.274 1.751–22.485 0.018
 None 11.805 1.373–101.479 0.025 34.369 2.073–569.752 0.014
 RT 1 (reference) 1 (reference)
 None 1.809 0.218–14.981 0.583 5.478 0.299–100.284 0.252
Peritoneal cytology
 Negative (30) 1 (reference)
 Positive (9) 1.452 0.555–3.794 0.447
LVSI
 Negative (4) 1 (reference)
 Positive (68) NA NA NA
PLN metastasis
 Negative (2) 1 (reference)
 Positive (74) NA NA NA

FIGO The International Federation of Gynecology and Obstetrics, HR hazard ratio, CI confidence interval, SCC squamous cell carcinoma, nSCC non-squamous cell carcinoma, PLN pelvic lymph node, LVSI lymphovascular space invasion, CCRT concurrent chemoradiotherapy, CT chemotherapy, RT radiotherapy.